Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00166595 · ClinicalTrials.gov registry record · Phase 1
Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)
A Phase 1 study of Child Development Disorders, Pervasive, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 4
- Study locations
NCT00166595: Completed Phase 1 study of Child Development Disorders, Pervasive, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT00166595 is a Phase 1 study of Child Development Disorders, Pervasive that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 100 participants, above the 84-participant average among 4 other Child Development Disorders, Pervasive trials with a reported enrollment target (19% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00166595, a Phase 1 study of Child Development Disorders, Pervasive, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine if the known differences in genes influence drug metabolizing enzymes and receptors that are involved in risperidone drug action. The study will determine if differences in these genes will change the concentration of risperidone in the blood over time in children in relation to side effects and clinical response to risperidone.
Conditions Studied
Interventions
- DRUG Risperidone
Study Locations (4)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- The Ohio State University Medical Center - Columbus
Michigan
- Children's Hospital of Michigan/Wayne State University - Detroit
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2003-02 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
What the finished NCT00166595 record still lists
NCT00166595 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 84-participant average among 4 other Child Development Disorders, Pervasive trials with a reported enrollment target (19% higher).
The record links to 1 condition, with Child Development Disorders, Pervasive appearing as the primary indexed condition, and to 1 intervention - of which Risperidone is the first listed.
NCT00166595 reports a single indexed study location in Ohio, Michigan, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00166595 about?
NCT00166595 is a clinical study titled "Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)". The purpose of this study is to determine if the known differences in genes influence drug metabolizing enzymes and receptors that are involved in risperidone drug action. The study will determine if differences in these genes will change the concentration of risperidone in the blood over time in ch...
What is the current status of trial NCT00166595?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2003-02. Estimated completion is 2005-03.
What conditions does trial NCT00166595 study?
This clinical trial studies the following conditions: Child Development Disorders, Pervasive.
What interventions are being tested in trial NCT00166595?
The interventions under investigation include: Risperidone (DRUG).
Who is sponsoring clinical trial NCT00166595?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00166595 being conducted?
This trial has 4 study locations across Michigan, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Child Development Disorders, Pervasive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)
COMPLETED · Phase 1
-
SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
RECRUITING
-
RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders
COMPLETED · NA
-
A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia